Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Evolus, Inc. (EOLS : NSDQ)
 
 • Company Description   
Evolus, Inc. is a medical aesthetics company. It focuses on providing physicians and patients in aesthetic procedures and treatments. The company focuses on the self-pay aesthetic market and its lead product candidate, DWP-450, is an injectable 900 kDa purified botulinum toxin type A complex. Evolus, Inc. is based in Irvine, California.

Number of Employees: 332

 
 • Price / Volume Information   
Yesterday's Closing Price: $9.21 Daily Weekly Monthly
20 Day Moving Average: 955,641 shares
Shares Outstanding: 64.48 (millions)
Market Capitalization: $593.82 (millions)
Beta: 0.97
52 Week High: $17.82
52 Week Low: $8.67
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -7.62% -11.63%
12 Week -10.06% -26.62%
Year To Date -16.58% -20.92%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
520 Newport Center Dr. Suite 1200
-
Newport Beach,CA 92660
USA
ph: 949-284-4555
fax: -
ir@evolus.com http://www.evolus.com
 
 • General Corporate Information   
Officers
David Moatazedi - President and Chief Executive Officer
Vikram Malik - Chairman
Sandra Beaver - Chief Financial Officer
Simone Blank - Director
David Gill - Director

Peer Information
Evolus, Inc. (BJCT)
Evolus, Inc. (CADMQ)
Evolus, Inc. (APNO)
Evolus, Inc. (UPDC)
Evolus, Inc. (IMTIQ)
Evolus, Inc. (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 30052C107
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 07/30/25
Share - Related Items
Shares Outstanding: 64.48
Most Recent Split Date: (:1)
Beta: 0.97
Market Capitalization: $593.82 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.18 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.47 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 07/30/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 2.16
EPS Growth
vs. Year Ago Period: -25.00%
vs. Previous Quarter: -257.14%
Sales Growth
vs. Year Ago Period: 15.49%
vs. Previous Quarter: -13.21%
ROE
06/30/25 - -
03/31/25 - -759.04
12/31/24 - -339.06
ROA
06/30/25 - -
03/31/25 - -20.14
12/31/24 - -18.08
Current Ratio
06/30/25 - -
03/31/25 - 2.34
12/31/24 - 2.40
Quick Ratio
06/30/25 - -
03/31/25 - 2.16
12/31/24 - 2.21
Operating Margin
06/30/25 - -
03/31/25 - -16.62
12/31/24 - -15.65
Net Margin
06/30/25 - -
03/31/25 - -20.40
12/31/24 - -18.93
Pre-Tax Margin
06/30/25 - -
03/31/25 - -20.15
12/31/24 - -18.69
Book Value
06/30/25 - -
03/31/25 - -0.10
12/31/24 - 0.09
Inventory Turnover
06/30/25 - -
03/31/25 - 6.90
12/31/24 - 6.46
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - 22.00
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - 95.65
 

Powered by Zacks Investment Research ©